155 related articles for article (PubMed ID: 8875453)
1. Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: its efficacy and problems.
Asada M; Kong J; Nakamura M; Tamaki N
Neurol Res; 1996 Aug; 18(4):342-4. PubMed ID: 8875453
[TBL] [Abstract][Full Text] [Related]
2. The effect of timing of intrathecal fibrinolytic therapy on cerebral vasospasm in a primate model of subarachnoid hemorrhage.
Findlay JM; Weir BK; Kanamaru K; Grace M; Baughman R
Neurosurgery; 1990 Feb; 26(2):201-6. PubMed ID: 2106630
[TBL] [Abstract][Full Text] [Related]
3. [Prevention of cerebral vasospasm by thrombolytic therapy using t-PA].
Miyamoto S; Kikuchi H; Nagata I
Nihon Rinsho; 1993 Dec; 51 Suppl():404-6. PubMed ID: 8121020
[No Abstract] [Full Text] [Related]
4. Innovations in aneurysmal subarachnoid hemorrhage: intracisternal t-PA for the prevention of vasospasm.
Bell TE; Kongable GL
J Neurosci Nurs; 1996 Apr; 28(2):107-13. PubMed ID: 8718759
[TBL] [Abstract][Full Text] [Related]
5. Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Ohman J; Servo A; Heiskanen O
J Neurosurg; 1991 Aug; 75(2):197-201. PubMed ID: 1906535
[TBL] [Abstract][Full Text] [Related]
6. Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator.
Mizoi K; Yoshimoto T; Takahashi A; Fujiwara S; Koshu K; Sugawara T
J Neurosurg; 1993 Mar; 78(3):430-7. PubMed ID: 8433145
[TBL] [Abstract][Full Text] [Related]
7. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH.
Findlay JM; Weir BK; Steinke D; Tanabe T; Gordon P; Grace M
J Neurosurg; 1988 Nov; 69(5):723-35. PubMed ID: 3141595
[TBL] [Abstract][Full Text] [Related]
8. Effect of BQ-123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys.
Kim CJ; Bassiouny M; Macdonald RL; Weir B; Johns LM
Stroke; 1996 Sep; 27(9):1629-33. PubMed ID: 8784140
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intrathecal administration of urokinase and tissue plasminogen activator on subarachnoid clot and chronic vasospasm in a primate model.
Hariton GB; Findlay JM; Weir BK; Kasuya H; Grace MG; Mielke BW
Neurosurgery; 1993 Oct; 33(4):691-6; discussion 696-7. PubMed ID: 8232810
[TBL] [Abstract][Full Text] [Related]
10. Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone.
Usui M; Saito N; Hoya K; Todo T
Neurosurgery; 1994 Feb; 34(2):235-44; discussion 244-5. PubMed ID: 8177383
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary clinical trial of intrathecal rt-PA (TD-2061) for the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage].
Sasaki T; Ohta T; Kikuch H; Takakura K; Usui M; Kondoh A; Tanabe H; Nakamura J; Yamada K
No To Shinkei; 1992 Nov; 44(11):1001-8. PubMed ID: 1296711
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Seifert V; Eisert WG; Stolke D; Goetz C
Neurosurgery; 1989 Oct; 25(4):590-8. PubMed ID: 2507953
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.
Findlay JM; Kassell NF; Weir BK; Haley EC; Kongable G; Germanson T; Truskowski L; Alves WM; Holness RO; Knuckey NW
Neurosurgery; 1995 Jul; 37(1):168-76; discussion 177-8. PubMed ID: 8587685
[TBL] [Abstract][Full Text] [Related]
14. [An experimental study on intrathecal injection of fibrinolytic agent for angiospasm following subarachnoid hemorrhage in the dogs (author's transl)].
Yoshida Y; Handa H; Hayashi T; Amo M; Aoki M; Kusuno K; Lee E; Uno T
Nihon Geka Hokan; 1979 Mar; 48(2):188-96. PubMed ID: 162263
[No Abstract] [Full Text] [Related]
15. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Zabramski JM; Spetzler RF; Lee KS; Papadopoulos SM; Bovill E; Zimmerman RS; Bederson JB
J Neurosurg; 1991 Aug; 75(2):189-96. PubMed ID: 1906534
[TBL] [Abstract][Full Text] [Related]
16. Effects of unilateral intrathecal administrations of low dose tissue-type plasminogen activator on clot lysis, vasospasm and brain phospholipid hydroperoxidation in a primate model of bilateral subarachnoid hemorrhage.
Suzuki H; Kanamaru K; Kuroki M; Sun H; Waga S; Miyazawa T
Neurol Res; 1998 Oct; 20(7):625-31. PubMed ID: 9785591
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of intrathecal thrombolytic therapy in a primate model of cerebral vasospasm.
Findlay JM; Weir BK; Gordon P; Grace M; Baughman R
Neurosurgery; 1989 Apr; 24(4):491-8. PubMed ID: 2496328
[TBL] [Abstract][Full Text] [Related]
18. A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Sasaki T; Ohta T; Kikuchi H; Takakura K; Usui M; Ohnishi H; Kondo A; Tanabe H; Nakamura J; Yamada K
Neurosurgery; 1994 Oct; 35(4):597-604; discussion 604-5. PubMed ID: 7808602
[TBL] [Abstract][Full Text] [Related]
19. The effect of tissue plasminogen activator (t-PA) on cerebral vasospasm in canine subarachnoid hemorrhage.
Chung WY; Lee LS
Zhonghua Yi Xue Za Zhi (Taipei); 1993 Nov; 52(5):298-306. PubMed ID: 8299025
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal fibrinolytic therapy after subarachnoid hemorrhage: dosage study in a primate model and review of the literature.
Findlay JM; Weir BK; Kanamaru K; Grace M; Gordon P; Baughman R; Howarth A
Can J Neurol Sci; 1989 Feb; 16(1):28-40. PubMed ID: 2493974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
